jRCT2031220333进行中（未招募）不适用
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgaris
试验速览
- 阶段
- 不适用
- 状态
- 进行中（未招募）
- 入组人数
- 240
- 主要终点
- -
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized Controlled Trial
- 干预模型
- Parallel Assignment
- 主要目的
- Treatment Purpose
- 盲法
- Double Blind
入排标准
- 年龄范围
- 9age old over 至 49age old under（—）
- 性别
- All
入选标准
- •Patients with Acne vulgaris 9 to 49 years old
排除标准
- •(1)Patients with concurrent presense of serious cardiac, hepatic, renal, plumonary, hematologic, or other diseases considered inappropriate for paticipation in the clinical study
- •(2)Patients with a history of hypersensitivity to investigational drug ingredients
- •(3)Pregnant or lactating women
结局指标
主要结局
-
Percentage change in total lesion count
次要结局
未报告次要终点
研究者
相似试验
招募中
3 期
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisAcne vulgarisJPRN-jRCT2031220334Tomoyuki Nishiura40
招募中
3 期
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisJPRN-jRCT2031220333Tomoyuki Nishiura240
进行中（未招募）
不适用
A phase III study to evaluate the efficacy and safety of M605110 in patients with acne vulgarisjRCT2031220334Maruho Co.,Ltd.40
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal CancerEUCTR2008-004672-50-ATovartis Pharma Services AG900
进行中（未招募）
1 期
A Phase III Study to Evaluate the Efficacy and Safety of Pazopanib Monotherapy Versus Placebo in Women Who Have not Progressed after First Line Chemotherapy for Epithelial Ovarian, Fallopian Tube, or Primary Peritoneal Cancer.Advanced Ovarian Cancer (FIGO Stage II, Stage III, and Stage IV epithelial ovarian, fallopian tube, or primary peritoneal cancer).MedDRA version: 20.0Level: PTClassification code 10033128Term: Ovarian cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2008-004672-50-DKGlaxoSmithKline Research & Development Ltd900